Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
26 hedge funds and large institutions have $7.88M invested in Vyant Bio, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 25 → 26 (+1)
14% less capital invested
Capital invested by funds: $9.2M → $7.88M (-$1.33M)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49.3K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$37.2K |
| 3 |
SIM
Spark Investment Management
New York
|
+$21.7K |
| 4 |
CPA
Court Place Advisors
Ellicott City,
Maryland
|
+$18.9K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
+$9.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$176K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$125K |
| 3 |
Renaissance Technologies
New York
|
-$72.1K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$49K |
| 5 |
Squarepoint
New York
|
-$36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TDC
26
Thompson Davis & Co
Richmond,
Virginia
| $1K | – | – | – |
|
|
TSS
27
Two Sigma Securities
New York
| – | -$125K | -451 | Closed |
|
|
28
Squarepoint
New York
| – | -$36K | -130 | Closed |
|
29
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$7K | -26 | Closed |
|
VYNT Hedge Fund Activity: Q1 2018 in Review
26 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q1 2018, worth a combined $7.88M — down 14% from $9.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VYNT positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $49.3K. The largest seller was UBS Group, cutting an estimated $176K.
- 26 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q1 2018, up from 25 in Q4 2017.
- Funds reported $7.88M of Vyant Bio, Inc. Common Stock stock for Q1 2018, down 14% quarter-over-quarter.
- 4 funds opened new Vyant Bio, Inc. Common Stock positions in Q1 2018 and 3 closed out, a net change of +1 holder.
- The largest Vyant Bio, Inc. Common Stock buyer in Q1 2018 was Vanguard Group, an estimated $49.3K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q1 2018 was UBS Group, an estimated $176K sold.
Based on aggregated 13F filings for Q1 2018.